Oxytocin in survivors of childhood-onset craniopharyngioma
- 1 September 2016
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 54 (2) , 524-531
Abstract
Quality of survival of childhood-onset craniopharyngioma patients is frequently impaired by hypothalamic involvement or surgical lesions sequelae such as obesity and neuropsychological deficits. Oxytocin, a peptide hormone produced in the hypothalamus and secreted by posterior pituitary gland, plays a major role in regulation of behavior and body composition. In a cross-sectional study, oxytocin saliva concentrations were analyzed in 34 long-term craniopharyngioma survivors with and without hypothalamic involvement or treatment-related damage, recruited in the German Childhood Craniopharyngioma Registry, and in 73 healthy controls, attending the Craniopharyngioma Support Group Meeting 2014. Oxytocin was measured in saliva of craniopharyngioma patients and controls before and after standardized breakfast and associations with gender, body mass index, hypothalamic involvement, diabetes insipidus, and irradiation were analyzed. Patients with preoperative hypothalamic involvement showed similar oxytocin levels compared to patients without hypothalamic involvement and controls. However, patients with surgical hypothalamic lesions grade 1 (anterior hypothalamic area) presented with lower levels (p = 0.017) of oxytocin under fasting condition compared to patients with surgical lesion of posterior hypothalamic areas (grade 2) and patients without hypothalamic lesions (grade 0). Craniopharyngioma patients’ changes in oxytocin levels before and after breakfast correlated (p = 0.02) with their body mass index. Craniopharyngioma patients continue to secrete oxytocin, especially when anterior hypothalamic areas are not involved or damaged, but oxytocin shows less variation due to nutrition. Oxytocin supplementation should be explored as a therapeutic option in craniopharyngioma patients with hypothalamic obesity and/or behavioral pathologies due to lesions of specific anterior hypothalamic areas. Clinical trial number: KRANIOPHARYNGEOM 2000/2007(NCT00258453; NCT01272622).Keywords
Funding Information
- Deutsche Kinderkrebsstiftung (DKS 2014)
This publication has 41 references indexed in Scilit:
- Modulating social behavior with oxytocin: How does it work? What does it mean?Hormones and Behavior, 2012
- Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-upEuropean Journal of Endocrinology, 2011
- Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patientsOrphanet Journal of Rare Diseases, 2011
- Surgical Management of Craniopharyngiomas in the Pediatric PopulationHormone Research in Paediatrics, 2010
- The Challenge of Translation in Social Neuroscience: A Review of Oxytocin, Vasopressin, and Affiliative BehaviorNeuron, 2010
- Oxytocin and the neural mechanisms regulating social cognition and affiliative behaviorFrontiers in Neuroendocrinology, 2009
- Oxytocin: The Great Facilitator of LifeProgress in Neurobiology, 2009
- Central nervous system control of food intake and body weightNature, 2006
- Oxytocin and an oxytocin agonist administered centrally decrease food intake in ratsPeptides, 1991